CGEM
Cullinan Therapeutics, Inc.
There isn't enough reported data to score CGEM yet.
CGEM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Strong |
CGEM's balance sheet is currently strong, but its revenue and profitability are weak. There isn't enough data to rate its cash flow.
CGEM PE Valuation
CGEM has no meaningful PE right now: it lost money over the past year.
CGEM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CGEM's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
CGEM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.68 | -$0.84 |
| Q2 2025 | -$3.51 | -$0.45 |
| Q1 2025 | -$3.08 | +$0.05 |
| Q4 2024 | -$3.12 | +$0.57 |
| Q3 2024 | -$2.84 | +$0.89 |
| Q2 2024 | -$3.06 | +$0.30 |
| Q1 2024 | -$3.13 | -354% |
| Q4 2023 | -$3.69 | -255% |
CGEM lost $3.68 per share over the past year, a bigger loss than the year before.
CGEM Quarterly Revenue
CGEM's revenue has slid since its 2021 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2021 | 7.2% | N/A |
CGEM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$38.2M | +$19.4M |
| Q1 2026 | -$46M | -$2.9M |
| Q4 2025 | -$38.1M | -$1.5M |
| Q2 2025 | -$57.6M | -$21.3M |
| Q1 2025 | -$43.2M | -$4.9M |
| Q4 2024 | -$36.6M | -$18.5M |
| Q3 2024 | -$34.1M | +$2K |
| Q2 2024 | -$36.3M | -$5.2M |
CGEM has burned cash in almost every quarter: −$180M over the past year, against −$150M the year before.
CGEM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +566K shares |
| 1 year | +9.9% | +5.8M shares |
| 3 years | +52% | +22.2M shares |
| 5 years | +49% | +21.5M shares |
| Available history | +235% | +45.6M shares |
CGEM has 65M diluted shares, up 9.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
CGEM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2023 | -1.1x | Net Cash |
| Q4 2022 | -1.1x | Net Cash |
| Q3 2022 | -1.7x | Net Cash |
| Q2 2022 | -2.3x | Net Cash |
CGEM has more cash than debt.
CGEM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 9.1 | Oversold |
CGEM's weekly RSI is 36 (neutral) and its Stochastic is 9 (oversold).
CGEM PE vs Healthcare Sector
| Metric | CGEM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CGEM has no meaningful PE right now: it lost money over the past year.
CGEM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.7 | 26% below |
| 20 week MA | $17.1 | 40% below |
| 50 week MA | $14.8 | 31% below |
| 100 week MA | $11.7 | 13% below |
| 200 week MA | $12.7 | 20% below |
CGEM is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
CGEM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $29.9 | $16.7 | -44% |
| 2022 | $16.7 | $10.2 | -39% |
| 2023 | $10.2 | $10.2 | -0.5% |
| 2024 | $10.2 | $12.0 | +18% |
| 2025 | $12.0 | $10.4 | -14% |
| 2026 YTD | $10.4 | $10.2 | -1.7% |
CGEM has finished lower in four of the last five years. It's down 1.7% so far in 2026.